Denosumab biosimilar by Celltrion for Osteoporosis: Likelihood of Approval

Denosumab biosimilar is under clinical development by Celltrion and currently in Phase I for Osteoporosis.

Boehringer looks ‘beyond stable’ to display the everyday realities of life with schizophrenia

Open the door to Boehringer Ingelheim’s apartment exhibit today in New York City, and you’ll see vast disarray — clothing and shoes piled on the

December 6, 2023

Trained immunity: its role in COVID-19 and potential in preparing for future infectious outbreaks

Researchers reported on the contribution of trained immune responses to protection against SARS-CoV-2 infections and future pandemics.

June 16, 2023

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024 – Biotech Investments

EQS-News: Heidelberg Pharma AG / Key word(s): Conference Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at

March 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.